Backed by National TV Commercials and Outdoor Campaigns Sponsored by MUSQ, ArriveAI, and Sustainable Green Team
NEW YORK CITY, NEW YORK / ACCESS Newswire / August 1, 2025 / New to The Street, the nation’s leading financial media platform, proudly announces the broadcast of Show #682, airing this evening at 9:30 PM PST on Bloomberg Television as sponsored programming. This episode showcases transformative companies driving innovation across artificial intelligence, veterinary health, blockchain, healthcare SaaS, and pharmaceutical sectors.
Featured Interviews on Episode #682 Include:
– DataVault Holdings Inc. (NASDAQ:DVLT) CEO Nathaniel Bradley highlights the company’s enterprise expansion, announcing the debut of AI agents powered by IBM watsonx.ai. This breakthrough enables corporate clients to securely monetize data using compliant, intelligent automation. DataVault AI’s growing partnerships with IBM and other tech leaders demonstrate its position at the forefront of AI + Web3 convergence-empowering businesses to unlock value from untapped data assets.
– PetVivo Holdings Inc. (NASDAQ:PETV) PetVivo continues its rapid commercial rollout of SPRYNG with OsteoCushion Technology, now adopted by over 1,200 veterinary clinics across the United States. The company is also making strategic inroads into the equine space through its new partnership with Commonwealth Thoroughbreds-aimed at advancing equine joint wellness and performance across top-tier racing circuits. This milestone reflects PetVivo’s growing leadership in the $3B+ animal therapeutics market, with SPRYNG providing a drug-free, minimally invasive solution to joint pain in companion and performance animals.
– Health In Tech Health In Tech presents its disruptive approach to benefits administration via an end-to-end SaaS platform designed for brokers, employers, and TPAs. The solution’s intuitive interface and real-time quoting tools deliver speed, efficiency, and scalability for today’s healthcare benefits landscape.
– FLOKI Leaders from FLOKI discuss their growing DeFi ecosystem and global presence, with recent expansions into financial education tools, community governance, and real-world payment infrastructure.
– NRx Pharmaceuticals (NASDAQ:NRXP) CEO Dr. Jonathan Javitt offers an update on the company’s late-stage pharmaceutical developments for bipolar depression, PTSD, and other CNS disorders, while continuing to advance FDA engagement for its proprietary pipeline.
National TV Commercial Support:
High-frequency national commercials and campaigns are airing in conjunction with the show for:
NRx Pharmaceuticals
ArriveAI
Sustainable Green Team (SGTM)
MUSQ – The Music ETF
Campaigns are focused on national television and the #1 NYC DMA, targeting high-investor-density zones and financial news audiences.
Cross-Platform Distribution & Outdoor Exposure:
All interviews are distributed via New to The Street’s YouTube channel (3.1M+ subscribers) and promoted across LinkedIn, Twitter/X, Instagram, and Facebook. Clients also receive billboard exposure across Times Square, Wall Street, and NYC Financial District bus shelters, with additional reach through syndicated earned media on ABC, NBC, and CBS local affiliates.
July Performance: A Record Month for Client Renewals
July saw 9 clients signing new or renewed media agreements across broadcast, digital, and outdoor campaigns – driven by demand for New to The Street’s unmatched national visibility and investor engagement platform. These results position the network as the leading multi-channel awareness engine for small- to mid-cap growth companies.
About New to The Street: New to The Street is a premier television business brand broadcasting sponsored programming on Fox Business and Bloomberg Television. With a loyal YouTube following of over 3.1 million subscribers, iconic outdoor billboard access, and strong earned media distribution, New to The Street delivers a 360-degree media solution for public and private companies seeking scale, credibility, and conversion.
HOUSTON, TEXAS / ACCESS Newswire / August 1, 2025 / Williams Hart & Boundas, a nationally recognized personal injury and mass torts law firm based in Houston, proudly announces its 40th anniversary. Since opening its doors in 1985, the firm has remained steadfast in its mission to advocate for individuals and families impacted by catastrophic injuries, defective products, environmental hazards, and corporate negligence.
Founded on the principles of integrity, compassion, and relentless advocacy, Williams Hart & Boundas LLP has recovered over $24 billion in verdicts and settlements on behalf of thousands of clients nationwide. Over the past four decades, the firm has built a reputation as a legal powerhouse, particularly in representing union workers, injured laborers, and victims of pharmaceutical negligence.
“Our 40th anniversary is not just a celebration of our legacy, it’s a testament to the trust our clients have placed in us and the results we’ve delivered,” said Managing Partner, John Eddie Williams, Jr. “This milestone reaffirms our commitment to stand up for the hardworking individuals who too often find themselves up against powerful corporations.”
Williams led the landmark 1998 litigation against Big Tobacco, which resulted in a $17.3 billion settlement for the State of Texas, the largest in U.S. history. Today, he continues to lead mass tort cases and personal injury claims that spotlight corporate negligence and systemic failure.
The firm’s track record includes landmark victories in asbestos litigation, pharmaceutical mass torts, refinery explosions, and rideshare assault cases. Williams Hart & Boundas LLP is also known for its deep roots in the Houston community, regularly partnering with local organizations, sponsoring educational events, and advocating for workplace safety reforms.
“As we look ahead, we’re more motivated than ever to innovate, expand access to justice, and protect those who need a strong voice in the legal system,” said Jim Hart, Senior Partner at the firm.
For more information about Williams Hart & Boundas LLP visit whlaw.com
###
About Williams Hart & Boundas Williams Hart & Boundas LLP is a Houston-based law firm with national reach, specializing in catastrophic accident cases. With a long history of trial success and a client-first approach, the firm is dedicated to securing justice for those harmed by negligence. Williams Hart & Boundas LLP brings the resources and perseverance needed to take on insurance companies and multinational corporations alike. The firm offers free case reviews and serves clients nationwide.
Media Contact: Toi C. Ames Marketing Strategist Phone: (713) 230-2200 Email: info@whlaw.com Website: whlaw.com
Multiple U.S. Judges Dismiss Actions Against EESystem, Affirming Company’s Right to Protect Its Reputation
LAS VEGAS, NV / ACCESS Newswire / August 1, 2025 / Energy Enhancement System (“EESystem”) today announced a series of decisive legal victories across Nevada, Florida, and New York, reinforcing the company’s nationwide defense against what it describes as a coordinated campaign of extortion and misinformation.
Legal Milestones
• Florida – March 31 2025 (S.D. Fla. Case No. 1:25-cv-00218) – The court granted EESystem’s motion to remand, calling Jason Shurka’s removal “objectively baseless” and awarding attorneys’ fees.
• Nevada – April 17 2025 (D. Nev. Case No. 2:25-cv-00471) – A second improper removal was remanded; the judge ruled “defendants yet again improperly removed this action.”
• Nevada TRO Clarification – May 2025 (Clark Cty. Dist. Ct. A-25-910216-B) – The court preserved key provisions of a Temporary Restraining Order that protect EESystem center owners and customers.
• New York – June 25 2025 (E.D.N.Y. Case No. 2:25-cv-01234) – The court denied a preliminary injunction sought by Robert Religa and Light System Inc., citing plaintiffs’ failure to show irreparable harm or likelihood of success.
These rulings follow public disclosures of threats demanding a ten-million-dollar “donation” from EESystem – evidence provided to law enforcement and the courts.
ABOUT ENERGY ENHANCEMENT SYSTEM
Energy Enhancement System (“EESystem”) is a pioneer in scalar-energy wellness technology with more than 3,000 installations worldwide and hundreds of public centers offering hourly access to EESystem sessions. Founded by Dr. Sandra Rose Michael, EESystem’s proprietary multi-unit installations generate bio-active energy fields designed to support cellular regeneration and holistic health.
The new cinematic trailer showcases Rust Mobile retaining the DNA of its PC predecessor, from cutthroat PvP to base raiding while offering the accessibility and flexibility of mobile
Players can get a hands-on experience of Rust Mobile as it makes its debut at gamescom from 20th to 24th August
Players are invited to pre-register at rustmobile.com
SHENZHEN, CN / ACCESS Newswire / August 1, 2025 / Level Infinite is thrilled to reveal gameplay features for Rust Mobile, the officially licensed mobile adaptation of the iconic PC survival game Rust. Recreating the brutal survival experience, Rust Mobile combines the original with mobile-first innovations and will see its public hands-on debut at gamescom 2025.
Officially licensed by Facepunch Studios, Rust Mobile stays true to the uncompromising spirit of the original, delivering a survival experience fans know and love. From open-world exploration and ruthless PvP combat to base building and the tension of trust and betrayal, the mobile version captures the essence of Rust.
Played from a first-person perspective in a real-time, fully immersive world, players face constant danger, whether from hostile wildlife or rival survivors. A fully explorable sandbox with dynamic day-night cycle, weather systems, and region-based biomes also adds deep environmental strategy. Core gameplay pillars like scavenging, crafting, building, raiding, and permadeath remain intact, where every decision can mean life or death.
In Rust Mobile players can choose how they want to survive, by going full PvP or playing at their own pace, offering more flexibility while staying true to the tension and danger of the original. Tailored for mobile lifestyles, Rust Mobile makes it easier than ever to jump into the survival experience, whether you’re at home, on your commute, or in between.
Exclusive Hands-on Demo at gamescom 2025
Rust Mobile will officially participate in gamescom 2025, the world’s largest gaming event, in Cologne from 20th to 24th August, marking the first-ever public hands-on demo of the game.
Players interested in survival and PvP should head to Hall 6.1, Booth C-051g, where they can try out the all-new Rust Mobile experience and also pick up exclusive posters and merch while supplies last.
Rust Mobile has undergone significant improvements in quality, gameplay systems, and content since the early tech test in Canada earlier this year and is ready for players to dive in and have an epic experience.
For more information about Rust Mobile or to pre-register, head to rustmobile.com, or follow the game on X, and YouTube. For gamescom opening times visit www.gamescom.global.
About Level Infinite
Level Infinite is Tencent’s global games brand, dedicated to delivering engaging and original gaming experiences to a worldwide audience, whenever and wherever they choose to play. The brand also provides a wide range of services and resources to a network of developers and partner studios around the world to help them unlock the potential of their games. Level Infinite is both publisher of breakout hit games like PUBG MOBILE, Honor of Kings and Goddess of Victory: NIKKE and a collaborative partner in games such as Dune: Awakening from Funcom, Warhammer 40K: Darktide and many more. To learn more about Level Infinite, visit www.levelinfinite.com
ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
In an exclusive interview, Eric Poma, Ph.D., CEO of Calidi Biotherapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Calidi’s pioneering approach to precision genetic medicine, enabled by its proprietary RedTail platform-an engineered, systemically delivered viral therapy designed to reach metastatic sites and deliver genetic medicines to treat tumors. The platform cloaks potent genetic payloads, such as IL-15 superagonist, within a human-derived envelope, allowing the virus to evade immune detection and circulate throughout the body. Preclinical data showcased at AACR and ASCO demonstrated that a single dose of Calidi’s lead candidate, CLD-401, not only eliminated metastatic tumors but also primed immune memory, offering the potential to prevent recurrence. With its scalable, non-integrating viral backbone and ability to deliver multiple genetic payloads, RedTail positions Calidi to address a vast oncology market projected to exceed $560 billion by 2033. The company is advancing toward IND filing in 2026, while exploring strategic pharma partnerships to support global commercialization. Calidi’s capital-efficient business model, strengthened balance sheet, and next-generation pipeline targeting both cancer and autoimmune diseases highlight its strong potential to deliver value to shareholders.
Dr. Steven Quay, CEO of Atossa Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Atossa’s strategic approach to redefining breast cancer treatment through its lead clinical candidate, (Z)-endoxifen – a next-generation SERM with best-in-class potential. With a focus on metastatic breast cancer, where current therapies often fall short, Atossa is advancing multiple Phase 2 studies that demonstrate strong clinical activity, improved tolerability, and a favorable safety profile. The presentation will highlight recent progress across key development programs, upcoming milestones, and how the Company’s differentiated science and capital-efficient model are designed to deliver both clinical impact and long-term shareholder value.
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company’s proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.
The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip’s products and services, please visit:
With IRS enforcement on the rise, self-employed truck drivers face growing financial and legal risks from unfiled returns and unpaid tax debt.
IRVINE, CALIFORNIA / ACCESS Newswire / August 1, 2025 / As IRS collections intensify in 2025, a growing number of self-employed truck drivers are facing serious consequences for falling behind on their taxes – including the suspension of commercial licenses and the seizure of federal tax refunds, according to a new warning from Clear Start Tax, a nationwide tax resolution firm.
The warning comes amid increased scrutiny of 1099 workers and rising reports of enforcement actions that are disproportionately impacting independent contractors in industries like trucking, where many drivers are responsible for handling their own tax filings and payments.
“Most 1099 truckers aren’t trying to avoid taxes – they’re just overwhelmed by inconsistent income, complicated deductions, and rising operating costs,” said a spokesperson from Clear Start Tax. “Unfortunately, the IRS doesn’t distinguish between intentional evasion and simple disorganization.”
Clear Start Tax notes that truckers with unpaid taxes or unfiled returns may see their CDL flagged during background checks or compliance reviews, which can jeopardize their livelihood. In some states, drivers have reported license holds or suspensions tied to unresolved tax issues.
“We’re seeing more cases where tax debt causes ripple effects: seized refunds, rejected loan applications, even blocked license renewals,” the spokesperson added. “For truckers who rely on every mile to make a living, these disruptions can be devastating.”
To avoid penalties, garnishments, and potential enforcement actions, Clear Start Tax urges 1099 truckers to act early – by filing any missing returns, reviewing estimated tax payments, and exploring relief programs like the IRS Fresh Start initiative.
“There are options to settle what you owe – often for less than the full amount – but waiting only limits what can be done,” said the spokesperson. “Truckers shouldn’t wait until the IRS pulls them off the road.”
About Clear Start Tax Clear Start Tax is a nationwide tax resolution company that helps individuals and small businesses resolve IRS and state tax debt through proven strategies and personalized support. From unfiled returns to wage garnishments, the team specializes in helping taxpayers regain control of their finances with compassion and clarity.
TORONTO, ON / ACCESS Newswire / August 1, 2025 / Eskay Mining Corp. (“Eskay” or the “Company”) (TSXV:ESK)(OTC PINK:ESKYF)(Frankfurt:KN7)(WKN:A0YDPM) is pleased to announce the offering of a non-brokered private placement of up to $2 million of flow-through units (the “Offering“) to be sold to charitable purchasers (the “Charity FT Units“) at a price of C$0.56 per Charity FT Unit.
Each Charity FT Unit will consist of one common share of the Company (each, a “FT Share“) and one-half of a common share purchase warrant, each of which qualifies as a “flow-through share” within the meaning of the Income Tax Act (Canada) (the “Tax Act“). Each full warrant (a “Warrant“) shall entitle the holder to purchase one common share (a “Warrant Share“) at a price of C$0.65 at any time on or before that date which is 24 months after the Closing Date (as herein defined).
The gross proceeds from the sale of Charity FT Units will be used to incur “Canadian exploration expenses” as defined in subsection 66.1(6) of the Tax Act and “flow through mining expenditures” as defined in subsection 127(9) of the Tax Act, and for a subscriber who is a qualifying individual under the Income Tax Act (British Columbia) (the “BC Tax Act“), qualifies as a “BC flow-through mining expenditure” as defined in section 4.721(1) of the BC Tax Act (“Qualifying Expenditures“). The Qualifying Expenditures will be incurred on or before December 31, 2026, and renounced to the subscribers with an effective date not later than December 31, 2025, in the aggregate amount of not less than the total amount of gross proceeds raised from the issue of the Charity FT Units.
Proceeds from the Offering will be expended on the Company’s 100% controlled and consolidated Eskay Project in the heart of the Golden Triangle, British Columbia.
The Offering is scheduled to close on or around August 22, 2025 (the “Closing Date” or “Closing“) and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The securities issue will have a hold period of four months and one day from the closing of the Offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Charity FT Units, nor shall there be any sale of the Charity FT Units in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Charity FT Units being offered will not be, and have not been, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, a U.S. person.
About Eskay Mining Corp:
Eskay Mining Corp (TSX-V:ESK) is a TSX Venture Exchange listed company, headquartered in Toronto, Ontario. Eskay is an exploration company focused on the exploration and development of precious and base metals along the Eskay rift in a highly prolific region of northwest British Columbia known as the “Golden Triangle,” 70km northwest of Stewart, BC. The Company currently holds mineral tenures in this area comprised of 177 claims (52,600 hectares).
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such as actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements.
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)
Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026
Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion
Reiterates 2025 expected year-end cash balance of approximately $6 billion
Announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025.
“In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Today, we are updating our 2025 financial framework, reducing the high end of this year’s expected revenue range by $300 million due to the timing of shipments. We continue to operate with financial discipline and are improving expected annual operating expenses in 2025 by approximately $400 million. Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.”
Recent progress includes:
Commercial Updates
COVID–19: The Company reported $114 million in Spikevax® sales in the second quarter of 2025, which includes $88 million of U.S. sales and $26 million of international sales. Moderna recently announced U.S. Food and Drug Administration (FDA) approval for the supplemental Biologics License Application (sBLA) for Spikevax in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. The Company’s COVID-19 vaccine (mRNA-1273) was previously available for pediatric populations under Emergency Use Authorization (EUA). Additionally, the Company announced it has received final approval from the European Medicines Agency for Spikevax targeting the LP.8.1 variant in individuals six months of age and older. Moderna also announced FDA approval for mNEXSPIKE® (mRNA-1283), a next-generation vaccine against COVID-19, for use in all adults aged 65 and older, as well as individuals aged 12-64 years with at least one underlying risk factor.
RSV: The Company reported negligible mRESVIA® sales in the second quarter of 2025. Moderna’s RSV vaccine for adults aged 60 years and older has been approved in approximately 40 countries. Additionally, Moderna recently announced that the FDA has approved mRESVIA (mRNA-1345), expanding the previous indication, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease.
Second Quarter 2025 Financial Results
Revenue: Total revenue for the second quarter of 2025 was $142 million, a 41% decrease from $241 million in the same period in 2024. The decline was primarily driven by lower COVID vaccine sales, which totaled $114 million in the quarter. Demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product.
Cost of Sales: Cost of sales for the second quarter of 2025 was $119 million, which included third-party royalties of $6 million, inventory write-downs of $38 million, and unutilized manufacturing capacity and wind-down costs of $52 million. Cost of sales was relatively flat compared to the same period in 2024. The increase in cost of sales as a percentage of net product sales, to 105% from 62% in the second quarter of 2024, was mainly driven by the impact of lower net product sales.
Research and Development Expenses: Research and development expenses for the second quarter of 2025 were $700 million, a 43% decrease compared to the same period in 2024. The reduction was primarily driven by lower clinical trial and manufacturing expenses, reflecting reduced production spending, program wind-downs, and the timing of trial activities across the Company’s respiratory vaccine portfolio.
Selling, General and Administrative Expenses: Selling, general and administrative expenses for the second quarter of 2025 were $230 million, a 14% decrease compared to the same period in 2024. The decline was primarily driven by broad-based cost reductions across consulting and external services, personnel-related expenses, and commercial and marketing activities, reflecting the Company’s continued cost discipline and ongoing efforts to streamline operations.
Income Taxes: Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.
Net Loss: Net loss was $(0.8) billion for the second quarter of 2025, compared to $(1.3) billion for the second quarter of 2024.
Loss Per Share: Loss per share was $(2.13) for the second quarter of 2025, compared to $(3.33) for the second quarter of 2024.
Cash Position: Cash, cash equivalents and investments as of June 30, 2025, were $7.5 billion, compared to $8.4 billion as of March 31, 2025. The decrease during the quarter was primarily due to ongoing research and development expenses and other operating activities.
2025 Financial Framework
Revenue: The Company updated its 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end of the range. This is primarily driven by the timing shift of deliveries of contracted revenue for the U.K. into the first quarter of 2026. For the second half of the year, Moderna expects a revenue split of 40-50% in the third quarter with the balance in the fourth quarter of 2025.
Cost of Sales: Cost of sales for 2025 is expected to be approximately $1.2 billion.
Research and Development Expenses: Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion.
Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2025 are projected to be approximately $1.1 billion.
Income Taxes: The Company continues to expect its full-year tax expense to be negligible.
Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.3 billion, lowered from previous expectations of approximately $0.4 billion.
Cash and Investments: Year-end cash and investments for 2025 are projected to be approximately $6 billion.
Recent Progress and Upcoming Late-Stage Pipeline Milestones
Respiratory vaccines:
Seasonal flu vaccine: In June, Moderna announced positive Phase 3 efficacy results for its seasonal flu vaccine (mRNA-1010), which demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. The Company is submitting mRNA-1010 data for publication, presenting data at medical conferences and preparing to file for FDA approval.
Seasonal flu + COVID vaccine: Moderna shared positive Phase 3 immunogenicity data for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 years and older at its 2024 R&D Day event. In May 2025, the Company announced that in consultation with the FDA, it had voluntarily withdrawn the pending Biologics License Application (BLA) for mRNA-1083 with the plan to resubmit after vaccine efficacy data from the Phase 3 trial of its investigational seasonal flu vaccine (mRNA-1010) are available. The Company is engaging with regulators on data requirements for resubmitting the BLA for mRNA-1083.
Latent and other vaccines:
Cytomegalovirus (CMV) vaccine: The Company shared 36-month durability data from a Phase 2 extension trial of its CMV vaccine candidate (mRNA-1647) at the ESCMID 2025 Global Congress. The pivotal Phase 3 study of mRNA-1647 is fully enrolled and has now accrued sufficient cases for evaluation of the primary endpoint of the study, evaluating its efficacy, safety and immunogenicity in the prevention of primary infection in women of childbearing age. Moderna is updating its analysis plan to incorporate additional secondary endpoints. The Company remains blinded and anticipates a Phase 3 final analysis in 2025.
Norovirus vaccine: The Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against norovirus (mRNA-1403) is accruing cases. The timing of the Phase 3 readout will be dependent on case accruals.
Oncology therapeutics:
Intismeran autogene: Moderna continues to make progress on advancing mRNA-4157 in the clinic. In collaboration with Merck, the Phase 3 clinical trial for adjuvant melanoma is fully enrolled. Two non-small cell lung cancer (NSCLC) Phase 3 studies for those with and without prior neoadjuvant treatment are enrolling. Separate randomized Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer are also enrolling, and a randomized Phase 2 study for adjuvant renal cell carcinoma is fully enrolled. Further, Moderna and Merck have launched a new Phase 2 study of first-line treatment for patients with metastatic melanoma.
Checkpoint adaptive immune modulation therapy (AIM-T): The Phase 1/2 study of mRNA-4359 is ongoing and the Phase 2 study, which includes cohorts in first-line metastatic melanoma and first-line metastatic NSCLC, is enrolling NSCLC patients.
The Company recently announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.
Rare disease therapeutics:
Propionic acidemia (PA) therapeutic: In an ongoing Phase 1/2 study designed to evaluate safety and pharmacology in trial participants with PA, Moderna’s investigational therapeutic (mRNA-3927) has been generally well-tolerated to date with no events meeting protocol-defined dose-limiting toxicity criteria. Early results suggest potential decreases in annualized metabolic decompensation event (MDE) frequency compared to pre-treatment, and the majority of patients have elected to continue on the open label extension study. The Company’s PA program is in a registrational study.
Methylmalonic acidemia (MMA) therapeutic: Moderna’s investigational therapeutic for MMA (mRNA-3705) has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. The FDA and Moderna have agreed on the pivotal study design. The Company expects to start a registrational study in 2025.
Moderna Corporate Updates
Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The Company anticipates a total headcount of under 5,000 by year-end.
Company Accolades
Moderna was named to the Boston Business Journal‘s annual list of the Most Charitable Companies in Massachusetts (third consecutive year)
Moderna was recognized as a top-scoring company on Disability:IN’s Disability Equality Index and a Best Place to Work for Disability Inclusion (fourth consecutive year)
Key 2025 Investor and Analyst Event Dates
Analyst Day: November 20
Investor Call and Webcast Information
Moderna will host a live conference call and webcast at 8:00 a.m. ET on August 1, 2025. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website.
The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
MODERNA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in millions, except per share data)
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
Revenue:
Net product sales
$
114
$
184
$
200
$
351
Other revenue1
28
57
50
57
Total revenue
142
241
250
408
Operating expenses:
Cost of sales
119
115
209
211
Research and development
700
1,221
1,556
2,284
Selling, general and administrative
230
268
442
542
Total operating expenses
1,049
1,604
2,207
3,037
Loss from operations
(907
)
(1,363
)
(1,957
)
(2,629
)
Interest income
81
111
171
231
Other income (expense), net
8
(27
)
4
(46
)
Loss before income taxes
(818
)
(1,279
)
(1,782
)
(2,444
)
Provision for income taxes
7
–
14
10
Net loss
$
(825
)
$
(1,279
)
$
(1,796
)
$
(2,454
)
Loss per share:
Basic and diluted
$
(2.13
)
$
(3.33
)
$
(4.64
)
$
(6.41
)
Weighted average common shares used in calculation of loss per share:
Basic and diluted
388
384
387
383
_______
1Includes grant, collaboration, licensing and royalty, and other miscellaneous revenue.
MODERNA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in millions)
June 30,
December 31,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$
1,279
$
1,927
Investments
3,852
5,098
Accounts receivable, net
36
358
Inventory
240
117
Prepaid expenses and other current assets
764
599
Total current assets
6,171
8,099
Investments, non-current
2,374
2,494
Property, plant and equipment, net
2,169
2,196
Right-of-use assets, operating leases
750
759
Other non-current assets
546
594
Total assets
$
12,010
$
14,142
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
175
$
405
Accrued liabilities
987
1,427
Deferred revenue
218
153
Other current liabilities
192
221
Total current liabilities
1,572
2,206
Deferred revenue, non-current
65
58
Operating lease liabilities, non-current
666
671
Financing lease liabilities, non-current
32
39
Other non-current liabilities
276
267
Total liabilities
2,611
3,241
Stockholders’ equity:
Additional paid-in capital
1,127
866
Accumulated other comprehensive income (loss)
23
(10
)
Retained earnings
8,249
10,045
Total stockholders’ equity
9,399
10,901
Total liabilities and stockholders’ equity
$
12,010
$
14,142
MODERNA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in millions)
Six Months Ended June 30,
2025
2024
Operating activities
Net loss
$
(1,796
)
$
(2,454
)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
245
213
Depreciation and amortization
96
77
Amortization/accretion of investments
(37
)
(55
)
Loss on equity investments, net
8
35
Other non-cash items
36
7
Changes in assets and liabilities:
Accounts receivable, net
310
729
Prepaid expenses and other assets
(150
)
3
Inventory
(122
)
(197
)
Right-of-use assets, operating leases
19
(62
)
Accounts payable
(203
)
(199
)
Accrued liabilities
(395
)
(464
)
Deferred revenue
68
146
Operating lease liabilities
(10
)
25
Other liabilities
(25
)
(67
)
Net cash used in operating activities
(1,956
)
(2,263
)
Investing activities
Purchases of marketable securities
(3,059
)
(3,390
)
Proceeds from maturities of marketable securities
3,424
3,536
Proceeds from sales of marketable securities
1,059
1,999
Purchases of property, plant and equipment
(120
)
(378
)
Purchase of intangible asset
(10
)
–
Net cash provided by investing activities
1,294
1,767
Financing activities
Proceeds from issuance of common stock through equity plans
17
47
Tax payments related to net share settlements on equity awards
(1
)
–
Changes in financing lease liabilities
(3
)
1
Net cash provided by financing activities
13
48
Effect of changes in exchange rates on cash and cash equivalents
1
–
Net decrease in cash, cash equivalents and restricted cash
(648
)
(448
)
Cash, cash equivalents and restricted cash, beginning of year
1,929
2,928
Cash, cash equivalents and restricted cash, end of period
$
1,281
$
2,480
Spikevax®, mRESVIA® and mNEXSPIKE® are registered trademarks of Moderna.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s 2025 financial framework, including its expected revenue range and ending cash balance; Moderna’s expected 2025 operating expenses; demand for Moderna’s products and Moderna’s ability to drive future sales growth; Moderna’s continued cost discipline; and anticipated milestones for Moderna’s pipeline programs, including catalysts over the next six months. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.
###
Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 Chris.Ridley@modernatx.com
Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 Lavina.Talukdar@modernatx.com
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna’s EP’949 patent.
This decision affirms the High Court’s initial ruling from July 2024 that the EP’949 patent is valid and infringed by Pfizer/BioNTech’s COVID-19 vaccine, Comirnaty®, which was subsequently appealed by Pfizer/BioNTech. With this ruling, the UK becomes the first jurisdiction globally to issue a second-instance decision confirming the validity of one of Moderna’s core mRNA patents. The High Court’s finding of infringement was not disputed by Pfizer/BioNTech on appeal.
“Moderna is pleased that the Court of Appeal has upheld the High Court’s finding that the EP’949 patent is valid and infringed by Pfizer/BioNTech,” said Moderna Chief Legal Officer Shannon Thyme Klinger. “Moderna will continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology.”
Elsewhere in Europe, recent legal developments have further strengthened Moderna’s intellectual property portfolio:
In Germany, the Regional Court found that Pfizer and BioNTech infringed Moderna’s modified mRNA patent and confirmed Moderna’s right to seek damages. An appeal is pending.
The European Patent Office (EPO) upheld the validity of EP’949 in opposition proceedings, further reinforcing the patent’s strength. An appeal is pending.
European patent EP’949 relates to chemically modified mRNA, one of Moderna’s foundational technologies that enables the development of mRNA-based medicines.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Moderna Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s plans to enforce its patent rights globally, including through seeking damages for infringement. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.
Amid growing public awareness of sun damage to the skin, Brusco Vision is urging patients and the media to consider a less discussed—but equally important—concern: the effects of ultraviolet (UV) radiation on the human eye. In a newly released article, “Protect Your Eyes from Harmful UV Rays with Custom Lens Replacement,” the Washington DC-based refractive surgery center details how its Custom Lens Replacement (CLR) procedure offers not only personalized vision correction but also lasting UV protection built directly into the lens implanted in the eye.
The average person is exposed to UV rays every day—while walking outside, driving, exercising, or even during cloudy weather when harmful rays still reach the eye. Prolonged UV exposure has been linked to cataracts, macular degeneration, photokeratitis, and in some cases, certain types of ocular cancer. Despite public education around wearing sunglasses, many individuals still experience cumulative UV damage due to inconsistent use or poor-quality eyewear. Brusco Vision addresses this widespread issue by offering a proactive, permanent solution through advanced intraocular lenses used in CLR. These lenses are made with materials and coatings that block 100% of UVA and UVB rays, providing a level of defense that sunglasses and traditional corrective lenses cannot consistently match.
Custom Lens Replacement is a refractive procedure similar to cataract surgery, in which the eye’s natural lens is removed and replaced with a personalized intraocular lens (IOL). Unlike glasses or contact lenses that sit on the surface of the eye, CLR works from within, correcting vision conditions such as nearsightedness, farsightedness, astigmatism, and presbyopia while also shielding the retina and other internal structures from the harmful effects of UV light. Many patients opt for CLR when they want to eliminate dependence on glasses but are not ideal candidates for LASIK due to thin corneas, early cataracts, or complex prescriptions. According to Dr. Michael Brusco, a board-certified refractive surgeon and founder of Brusco Vision, this procedure represents a significant advancement in both vision correction and preventive eye health.
Another key advantage of Custom Lens Replacement is the reduction of glare and improvement in visual comfort. Patients who struggle with reflected sunlight from roads, glass surfaces, or water often experience significant relief after the procedure. The advanced lens technology used in CLR may include optional polarization, mirror coatings, or anti-reflective layers that manage how light is filtered into the eye. While high-quality sunglasses can provide temporary relief, the permanent benefit of a built-in solution helps patients enjoy greater comfort without constantly managing their environment or accessories. This becomes especially relevant for people who drive frequently or work in bright conditions where visual clarity and focus are essential for safety and performance.
In addition to UV protection and reduced glare, Custom Lens Replacement offers the long-term benefit of visual clarity without the hassle of glasses or contact lenses. Many patients report sharper visual acuity across a range of distances, with the added benefit of not having to switch between different types of eyewear. The ability to combine vision correction and UV defense in a single procedure is appealing to patients looking to simplify their daily routines and protect their eye health in the long run. In the article, Brusco Vision underscores that patients can avoid the ongoing cost and inconvenience of multiple prescriptions, scratched lenses, or forgotten sunglasses, while investing in a solution that protects their eyes from future damage.
Dr. Brusco emphasizes that every Custom Lens Replacement procedure at Brusco Vision is highly personalized to meet each patient’s vision goals, lifestyle, and unique ocular anatomy. Through advanced diagnostics and detailed consultations, the team selects the right intraocular lens to deliver both clarity and long-term protection. This approach is especially beneficial for patients with early-stage cataracts who want to address their vision proactively rather than waiting for the condition to progress. Because cataracts and macular degeneration are closely linked to UV exposure, CLR serves not only as a vision correction procedure but also as a preventive measure against future disease—making it a smart investment in long-term eye health.
Brusco Vision is known for delivering exceptional refractive care with a commitment to precision and innovation. The practice remains focused on educating the public and medical community about the evolving role of Custom Lens Replacement in comprehensive eye health. As awareness grows about the cumulative effects of UV damage to the eyes, the practice is encouraging more patients to consider whether this permanent solution could offer them better protection than external lenses or lifestyle adjustments alone. Dr. Brusco and his team continue to advocate for early intervention and believe that better education around UV risks will lead to more informed decisions and healthier long-term outcomes for patients.
Reporters interested in covering this topic or seeking expert commentary from Dr. Brusco are encouraged to reach out for interviews or background information. As one of the leading voices in refractive surgery and patient-centered care, Dr. Brusco offers insight into both the clinical science and practical applications of CLR, especially as it relates to preventive eye health. His perspective is especially timely as eye care professionals continue to see rising interest in procedures that do more than correct vision—they also aim to prevent future disease.
